San Diego-centered Viking Therapeutics marked by itself as a serious competitor in the weight loss drug market in February after revealing promising knowledge from a mid-phase demo of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when provided to be a weekly injection As well as in March the compan